Heated chemo showdown: one round or three for rare belly cancer?
NCT ID NCT07328737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving three rounds of heated chemotherapy directly into the abdomen after surgery works better than just one round for people with pseudomyxoma peritonei, a rare cancer that spreads in the belly. About 132 adults will be randomly assigned to one or three treatments. Researchers will track survival, side effects, and quality of life over several years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hyperthermic intraperitoneal chemotherapy (HIPEC)
- What this could lead to
- If more cycles work better, this could establish a more effective treatment schedule for pseudomyxoma peritonei, potentially improving long-term survival.
- What could go wrong
- This is a mid-stage trial with 132 participants, so results may not apply to all patients. Extra chemotherapy cycles could increase side effects like infections or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 132 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol; 2. Age 18-70 years; 3. Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade; 4. Karnofsky performance status (KPS) \>60; 5. Adequate function of major organs as follows: 1. Hematology: WBC ≥3.5×10\^9/L, ANC ≥1.0×10\^9/L, LC ≥0.5×10\^9/L, PLT ≥80×10\^9/L, Hb ≥90 g/L; 2. Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN); 3. Renal function: serum creatinine \<1.2×ULN; 4. Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN; 5. Cardiopulmonary function sufficient to tolerate major surgery and HIPEC; (5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study; Exclusion Criteria: 1. Metastases to lung, brain, bone, or liver; 2. AST, ALT, or TBIL ≥2×ULN; 3. Serum creatinine ≥1.2×ULN; 4. Severe mesenteric contraction; 5. Major organ dysfunction that cannot support the planned procedures; 6. Concomitant hematological disorders or other malignancies; 7. Acute or subacute infectious disease; 8. History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history; 9. Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation; 10. Any other condition deemed unsuitable for enrollment by the investigator;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pseudomyxoma peritonei are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tsinghua University affiliated Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, Changping, 102218, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy during surgery extend life for peritoneal cancer patients?
- Patient stories could unlock new treatments for rare appendix cancer
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Common diabetes drug may slow rare abdominal cancer
- Lower dose of heated chemo may be just as effective for rare abdominal cancer
- Keeping patients at the right temperature during surgery may protect their brain